Clients trust Mark Remus to solve their patent disputes quickly, efficiently, and strategically. He has served as lead counsel on numerous patent infringement litigation matters, and he has successfully represented clients in jury trials, bench trials, and appeals to the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court. Intellectual Asset Management (IAM) magazine writes that Mark is “[a]lways one of the best lawyers in the courtroom, he has an even temperament for litigation and is precise in everything he does,” calling him “quite a force to be reckoned with.” Clients recognize Mark for being “always well-prepared and conscientious” and “tough when the situation requires it.”
Mark has experience with a wide range of technologies, including medical devices, industrial equipment, and electrical components and systems. Mark has extensive experience with pharmaceutical litigation under the Hatch-Waxman Act. He has advised clients on a wide range of drug products and technologies, including new chemical entities, complex formulations, polymorphs, methods of treatment, and extended-release formulations.
Mark consistently has been named by publications and in lists that honor attorney achievement, including the IAM Patent 1000 (2022). Mark has also been recognized as a Leading Life Sciences Lawyer by LMG Life Sciences (2022/2023).
Prior to joining Crowell & Moring, Mark was a shareholder at Brinks Gilson & Lione.
Education
- University of Illinois, B.S. Chemical Engineering (1994) with distinction
- University of Illinois College of Law, J.D. (1997) cum laude
Affiliations
View More